Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Open-Label Study of Parsaclisib, a PI3Kδ Inhibitor, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)

NCT04434937 is registered in ClinicalTrials.gov with Incyte Biosciences Japan GK as lead sponsor.

NCT NCT04434937
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04434937 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Open-Label Study of Parsaclisib, a PI3Kδ Inhibitor, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)
Lead sponsor
Incyte Biosciences Japan GK
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2020
Completion date
October 13, 2023
Enrollment
42 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma